ANI Pharmaceuticals | ANIP - Операционные расходы





Операционные расходы Изменить Дата
AbbVie USD 10.27B 538M 2026-03
ANI Pharmaceuticals USD 562.3M 344.37M 2026-03
Assertio Holdings USD 105.8M 12.5M 2025-09
Aurora Cannabis CAD 129.98M 16.05M 2025-12
Canopy Growth CAD 87.2M 6.22M 2025-12
Eli Lilly USD 10.02B 285M 2026-03
Emergent BioSolutions USD 555.9M 242.7M 2023-06
Heron Therapeutics USD 40.55M 1.46M 2025-12
Hikma Pharmaceutical USD 1.34B 702M 2025-12
Knight Therapeutics CAD 126.9M 8.29M 2025-12
Nektar Therapeutics USD 40.9M 44.19M 2025-12
Novartis USD 9.8B 23M 2025-12
Omeros USD 59.16M 20.13M 2024-06
Perrigo USD 935.6M 89.6M 2026-03
Sun Pharmaceuticals INR 111.11B 6.97B 2025-09
Teva Pharmaceutical Industries USD 3.22B 1000M 2026-03